Abstract:Objective To evaluate the long-term clinical outcomes of Gamma Knife surgery (GKS) for residual or recurrent non-functioning pituitary adenomas (NFPAs) after surgery and the role of GKS in the management of NFPAs via a multicenter study. Methods Between Jan 2000 and Jan 2015, 451 patients with postsurgical residual or recurrent NFPAs undergoing GKS from four gamma knife centers were enrolled in this study according to the inclusion criteria. Of them, 219 were male and 232 were female. Their ages ranged from 13 to 79 years old with a median age of 50. The median tumor volume was 4.0 m3 (0.79~55.3 m3). The median margin dose was 14Gy (8~21 Gy), and the median maximum dose was 30Gy (16~42 Gy). Results The median duration of follow-up was 50 months (6~213 months). The tumor control rate of this cohort was 94%. The cumulative tumor control rates of 3-, 5-, 8-, 10-, and 15-year were 95%, 93%, 92%, 88%, and 80% respectively. The rate of new onset hypopituitarism was 22%. The rates of new or worsening visual dysfunction, the abducens nerve dysfunction, and the oculomotor nerve dysfunction were 8%, 1.3%, and 1% respectively. Conclusion From the multicenter study, GKS provides a high tumor control and a low complication rate for postsurgical residual or recurrent NFPAs, and should be considered as the routine adjuvant treatment of residual or recurrent NFPAs after surgery.